{"filings":[{"id":2382242,"accession_number":"0001493152-26-039472","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2026-08-20T20:05:31+00:00","items":["8.01"],"status":"ready","headline":"RenovoRx regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice Dec 31, 2025 for bid price below $1.00 for 30 consecutive days.","Confirmed Aug 20, 2026 that bid price was $1.00+ for 10 straight days (Aug 6-19).","Nasdaq considers matter closed; company now compliant with Listing Rule 5550(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2244046,"accession_number":"0001193125-26-349157","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K/A","filed_at":"2026-08-13T20:06:20+00:00","items":["2.02","9.01"],"status":"ready","headline":"RenovoRx Q2 revenue $909k, up 115% YoY; raises FY26 guidance to $3.75-4.25M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 revenue $909k, up 61% QoQ and 115% YoY; gross margin 84.3%.","FY2026 revenue guidance raised to $3.75M-$4.25M from prior $3.0M-$4.0M.","Phase III TIGeR-PaC fully enrolled; completion expected H1 2027, topline H2 2027.","First commercial RenovoCath use in sarcoma; active cancer centers up to 21 from 16.","Net loss $2.9M ($0.06/share); cash $9.5M, sufficient into H2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2217204,"accession_number":"0001193125-26-346894","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2026-08-12T20:16:29+00:00","items":["2.02","9.01"],"status":"ready","headline":"RenovoRx Q2 revenue $909K, up 115% YoY; raises FY2026 guidance to $3.75-4.25M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 revenue $909K, up 61% QoQ and 115% YoY; record quarter, 83% of FY2025 total revenue.","FY2026 revenue guidance raised to $3.75-4.25M from $3-4M, implying ~241-286% YoY growth.","21 active commercial cancer centers (+30% from 16 in Q1); 63 in pipeline; Q3 revenue expected to exceed Q2.","Phase III TIGeR-PaC fully enrolled; 78/86 events; completion H1 2027, topline H2 2027.","First RenovoCath use in sarcoma patient; cash $9.5M, sufficient into H2 2027; break-even target Q4 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2051683,"accession_number":"0001493152-26-035995","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2026-08-04T20:10:21+00:00","items":["8.01","9.01"],"status":"ready","headline":"RenovoRx to highlight TAMP platform at JonesTrading KOL webinar on Aug 13, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RenovoRx to participate in JonesTrading KOL webinar on pancreatic cancer on Aug 13, 2026 at 1:30 p.m. ET.","RenovoCath sales of ~$1.1M in 2025 and record $563K in Q1 2026.","Full enrollment in Phase III TIGeR-PaC trial expected very near term; final data readout mid to late 2027.","IAG (intra-arterial gemcitabine via RenovoCath) has Orphan Drug Designation for pancreatic and bile duct cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1397718,"accession_number":"0001493152-26-031662","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2026-07-02T12:30:17+00:00","items":["3.01"],"status":"ready","headline":"RenovoRx receives Nasdaq extension to Dec 28, 2026 to regain $1 minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on July 1, 2026 granting additional 180-day compliance period until Dec 28, 2026.","Previously reported deficiency on Dec 31, 2025 for failing to meet $1.00 minimum bid price requirement.","Must have closing bid price ≥ $1.00 for 10 consecutive business days during second period to regain compliance.","If not compliant by Dec 28, 2026, Nasdaq will delist common stock; company may appeal to Hearings Panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1362356,"accession_number":"0001493152-26-031303","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2026-06-30T20:55:23+00:00","items":["5.07","9.01"],"status":"ready","headline":"RenovoRx stockholders elect directors, approve equity plan amendment, ratify auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected with 12.9M+ votes for each; broker non-votes of 9.6M.","Amendment to 2021 Omnibus Equity Incentive Plan approved: 9.7M for, 3.6M against; adds 2,000,000 shares (4.4% of outstanding).","Ratification of Frank, Rimerman + Co. LLP as auditor for FY 2026: 21.9M for, 477k against.","Approximately 22.8M shares (50.6% of 45.1M outstanding) present or represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":443004,"accession_number":"0001193125-26-224080","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2026-05-14T20:17:07+00:00","items":["2.02","9.01"],"status":"ready","headline":"RenovoRx Q1 revenue $563K (+136% QoQ); net loss $3.5M; reaffirms FY revenue guidance $3-4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $563,000, up 136% from Q4 2025; exceeds 50% of total FY2025 revenue.","Net loss $3.5M vs $2.4M a year ago; cash $12.4M with runway into H2 2027.","Active commercial cancer centers grew to 16 from 8 at year-end 2025; target 36 by year-end 2026.","Phase III TIGeR-PaC enrollment at 106 of 114 patients (93%); full enrollment expected by June 2026.","FY 2026 revenue guidance reaffirmed at $3-4 million."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":563000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105685,"accession_number":"0001493152-26-013653","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"RenovoRx reports 2025 revenue of $1.1M from RenovoCath; net loss $11.2M; cash $13M after $10M financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 revenue $1.1M vs $43K in 2024; first full year of RenovoCath commercialization; cost of revenue $327K, gross profit $796K.","Net loss $11.2M ($0.32 diluted EPS) vs $8.8M ($0.40) in 2024; R&D spend $6.3M, SG&A $7.0M.","Phase III TIGeR-PaC trial: 104 patients randomized (target 114), 72 deaths; enrollment completion expected mid-2026, final data 2027.","12 U.S. cancer centers actively using RenovoCath as of Feb 2026; 33 centers in pipeline; $400M peak U.S. TAM for device.","Appointed Mark Voll as CFO in Feb 2026; closed $10M private placement (net $9.2M) on Mar 20, 2026; cash $13M on hand."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105684,"accession_number":"0001493152-26-013080","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"RenovoRx appoints Ramtin Agah, MD as Executive Chairman; $450K salary + bonus","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ramtin Agah, MD appointed Executive Chairman effective Feb 27, 2026; continues as Chief Medical Officer.","$450,000 annual base salary, discretionary bonus up to 40% of base (first bonus payable in 2027 for 2026).","Eligible for annual grants of stock options and other equity awards under Company's 2021 Omnibus Equity Incentive Plan.","Employment at-will; prior consulting agreement replaced; existing Change in Control and Severance Agreement remains in effect.","CEO Shaun Bagai remains principal executive officer; Dr. Agah reports directly to Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105683,"accession_number":"0001493152-26-012058","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"RenovoRx raises $10M via common stock and milestone warrants in oversubscribed offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$10M gross from sale of 8.4M shares, 2.2M pre-funded warrants, and 5.3M milestone warrants to 15 investors (including insiders).","Milestone warrants (50% coverage) expire upon $1.5M quarterly product revenue or Mar 30, 2029; exercise price $1.751 (institutional), $1.933 (insiders).","Proceeds to boost RenovoCath commercial rollout and fund Phase III TIGeR-PaC trial to full enrollment by mid-2026.","Insider participation at $1.0288/share vs $0.938 for institutions to comply with Nasdaq pricing rules.","Company must file resale registration within 30 days; liquidated damages of up to 10% of subscription amount if delayed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105682,"accession_number":"0001493152-26-005437","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"RenovoRx appoints Mark Voll as CFO; Kocak resigns as Principal Accounting Officer but remains Controller","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Voll, age 72, appointed CFO effective Feb 4, 2026; also serves as Principal Financial and Accounting Officer.","Ronald B. Kocak resigned as Principal Accounting Officer effective Feb 3, 2026; remains VP and Controller with same salary.","Voll receives $250/hour (50% cash, 50% RSUs) plus initial grant of 60,000 unvested RSUs under 2021 Omnibus Plan.","Voll brings 30+ years finance/accounting experience; led IPOs at Techwell, Montage, Aquantia.","Company generated ~$900K revenue from RenovoCath sales in first nine months of 2025; repeat orders growing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105681,"accession_number":"0001493152-26-000113","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"RenovoRx receives Nasdaq deficiency notice for minimum bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice Dec 31, 2025; closing bid price below $1.00 for 32 consecutive business days.","Has 180 calendar days, until June 30, 2026, to regain compliance by closing at $1.00 for 10 consecutive days.","If non-compliant by June 30, 2026, may qualify for an additional 180-day period with reverse stock split option.","Failure to cure could lead to delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121966,"accession_number":"0001493152-25-023604","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"RenovoRx enters $3.7M ATM equity sales agreement with JonesTrading","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $3,723,029 in common stock may be sold at-the-market through JonesTrading; 3.0% commission.","Shares issued under effective shelf registration S-3 (333-268302) and new prospectus supplement filed Nov 14, 2025.","Company also filed new S-3 to extend current shelf's usability for 180 days past Nov 21, 2025 expiration.","No assurances any shares will be issued; company reimburses agent specified expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121965,"accession_number":"0001493152-25-022325","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"RenovoRx reports Q3 revenue $266K, net loss $2.9M; expands to 14 approved cancer centers","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $266K from RenovoCath sales; year-to-date revenue ~$900K from zero prior year.","Net loss $2.9M for Q3 vs $2.5M in Q3 2024; cash $10M as of Sept 30, 2025.","Phase III TIGeR-PaC trial enrollment expected to complete early 2026 with final data in 2027.","Expanded from 5 to 14 approved cancer center customers for RenovoCath since start of 2025.","Hired Philip Stocton as Senior Director of Sales and added two regional sales managers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":885000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138662,"accession_number":"0001641172-25-024147","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"RenovoRx Q2 2025 revenue $422k from RenovoCath; DMC recommends continue Phase III trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue $422k from commercial RenovoCath sales, up from $0 in Q2 2024.","Cash $12.3M as of June 30, 2025; net loss $2.9M vs $2.4M YoY.","Independent DMC recommends continue Phase III TIGeR-PaC trial after second interim analysis; 95 patients randomized, 61 events.","13 cancer centers approved as customers (up from 5 in Q1); 4 have used device and placed repeat orders.","Hired Phil Stocton as Senior Director of Sales; launched PanTheR post-marketing registry study."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":619000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156116,"accession_number":"0001641172-25-016512","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"RenovoRx shareholders elect directors, approve equity plan amendment, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected; three directors received >3.2M withheld votes each.","Equity plan amended: 913,794 shares added (2.5% of outstanding); evergreen increased from 3% to 5%.","Ratification of Frank, Rimerman + Co. as auditor for FY2025 passed with 19.13M votes for, 949K against.","Approximately 20.09M shares voted out of 36.55M outstanding, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156115,"accession_number":"0001641172-25-010895","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"RenovoRx Q1 revenue ~$200K from RenovoCath sales; TIGeR-PaC trial 91 patients randomized","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 revenue of ~$200K from commercial RenovoCath sales, exceeding internal expectations; gross profit $103K.","Cash $14.6M as of Mar 31, 2025, up from $7.2M at Dec 31, 2024; funds commercial scale-up and trial completion.","Phase III TIGeR-PaC trial: 91 patients randomized, 56 events (second interim analysis triggered); DMC review expected Q3 2025.","Net loss $2.4M vs $1.1M in Q1 2024 due to higher operating costs and lower warrant liability gain.","Management and Board purchased ~143K shares; new U.S. patent issued for TAMP platform (19 patents total)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":197000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156114,"accession_number":"0001641172-25-002009","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"RenovoRx reports first RenovoCath revenue of $43k in Q4 2024; TIGeR-PaC trial 79% enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First commercial RenovoCath revenue ~$43k in Q4 2024; sequential growth expected in 2025.","TIGeR-PaC trial: 90 of 114 patients randomized; 50 of 86 events; 2nd interim analysis at 52nd event expected Q2 2025.","Cash $7.2M at 2024 year-end; $10.9M net raised in Feb 2025 public offering.","Net loss $8.8M in 2024 vs $10.2M in 2023; R&D $6.0M, SG&A $5.0M.","Shares outstanding 36.5M as of March 25, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":197000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174554,"accession_number":"0001493152-25-005559","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"RenovoRx prices $12.1M underwritten public offering of 11.5M shares at $1.05 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 11,523,810 shares at $1.05/share; gross proceeds ~$12.1M, net ~$10.9M after underwriting discounts and expenses.","Closing expected February 10, 2025; underwriter warrants issued for 576,191 shares at $1.21/share.","Proceeds to fund Phase III TIGeR-PaC study and commercial activities for RenovoCath device.","Titan Partners Group acted as sole bookrunner for the firm commitment offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191512,"accession_number":"0001493152-24-045373","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RenovoRx Q3 2024 net loss $2.5M; cash $9.6M, trial interim analysis targeted late 2024/early 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.5M in Q3 2024 vs $1.4M loss in Q3 2023; R&D flat at $1.7M, G&A down to $1.2M.","Cash $9.6M at Sept 30, sufficient to fund next TIGeR-PaC interim analysis and current RenovoCath commercialization.","Phase III TIGeR-PaC trial in LAPC: next interim analysis triggered by 52nd event (estimated late 2024/early 2025); full enrollment expected H1 2025.","RenovoCath commercialization progressing; increased production with Medical Murray; potential near-term revenue in 2025 via direct or partner channels.","Promoted Robert Strasser to VP R&D & Operations; enrolled first patient at University of Nebraska Medical Center for TIGeR-PaC trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207994,"accession_number":"0001493152-24-038108","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"RenovoRx increases RenovoCath production, expands Medical Murray partnership with warrant for 709,500 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RenovoRx boosts production of FDA-cleared RenovoCath catheter due to strong physician demand; over 500 procedures performed.","New work order with Medical Murray; RenovoRx issues warrant for up to 709,500 shares to incentivize manufacturing milestones.","Phase III TIGeR-PaC trial in pancreatic cancer continues; 52nd event (interim analysis) expected late 2024 or early 2025.","CEO expects commercial launch of RenovoCath as standalone device to generate revenue during 2025; sufficient cash on hand.","Robert Strasser promoted to VP of R&D and Operations to lead manufacturing and commercial strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207993,"accession_number":"0001493152-24-032812","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"RenovoRx appoints Frank Rimerman as auditor effective Aug 12, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Baker Tilly resigned effective Aug 13, 2024 after filing Q2 10-Q.","Audit Committee approved Frank Rimerman engagement on Aug 12, 2024.","No disagreements or reportable events occurred with former auditor.","Frank Rimerman previously served as RenovoRx's auditor for FY 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225520,"accession_number":"0001493152-24-023128","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"RenovoRx enters severance deal with VP/Controller Kocak; annual meeting re-elects six directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Severance provides 50% of base salary on qualifying termination; 100% plus full equity vesting if within 12 months of a change in control.","Kocak also receives 6 months COBRA (12 months in change in control) and pro-rata bonus.","At June 6 annual meeting, all six nominees re-elected: Bagai, Agah, Macfarlane, Marton, Ryan, Spiegel.","Agreement mirrors terms for other RenovoRx executive officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225519,"accession_number":"0001493152-24-017745","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["4.01","5.02","9.01"],"status":"ready","headline":"RenovoRx auditor Baker Tilly to resign; CEO salary restored with bonuses after $17.2M equity raise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Baker Tilly resigns as auditor effective after Q2 2024 10-Q filing (expected Aug 2024); no accounting disagreements.","Material weakness in internal controls for FY 2023 and 2022; prior going concern opinion noted.","CEO Shaun Bagai salary increased to $520k (from $390k); three other NEOs also received salary restorations.","One-time cash bonuses awarded to NEOs totaling ~$292k, tied to $17.2M equity financing in 2024.","Company expects overall annual executive comp to decrease due to earlier management changes and promotions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225518,"accession_number":"0001493152-24-015192","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"RenovoRx regains Nasdaq compliance after $17.2M fundraising; hearing cancelled","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq confirmed RenovoRx met $2.5M minimum stockholders' equity requirement; prior deficiency remedied.","Company raised $17.2M in gross proceeds in 2024, extending cash runway into 2026.","Hearing before Nasdaq Hearings Panel cancelled; no ongoing monitor required.","Management to focus on Phase III TIGeR-PaC trial progress, TAMP pipeline expansion, and business development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225517,"accession_number":"0001493152-24-014742","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"RenovoRx raises $11.1M, believes it has regained Nasdaq equity compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed $11.1M private placement of common stock and warrants on April 11, 2024.","Company previously faced delisting for stockholders' equity below $2.5M.","Believes new capital brings it into compliance; awaiting Nasdaq confirmation.","If confirmed, monitoring continues; non-compliance could reappear at next periodic report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225516,"accession_number":"0001493152-24-014559","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["3.02","8.01","7.01","9.01"],"status":"ready","headline":"RenovoRx closes $11.1M private placement; total 2024 raise $17.2M, funds Phase III trial into 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $11.1M from private placement of common stock, pre-funded, Series A, B, and placement agent warrants.","Net proceeds estimated at ~$9.6M; total gross proceeds raised in 2024 now $17.2M from two placements.","Issued 6,960,864 common shares, pre-funded warrant for 951,500 shares, Series A/B warrants for 7.9M and 3.96M shares.","Proceeds for working capital, Phase III TIGeR-PaC trial in LAPC, and pipeline expansion into additional cancer indications.","Company expects cash runway into 2026; second interim analysis for TIGeR-PaC estimated in late 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225515,"accession_number":"0001493152-24-014069","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"RenovoRx raises $11.1M via private placement of shares and warrants; funds Phase III trial into 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$11.1M from sale of 7,912,364 shares and warrants at $1.4075 per unit.","Warrants include Series A (5-year, $1.22 strike) and Series B (2-year, $1.22 strike), 150% warrant coverage.","Cash runway extended into 2026; combined with prior $6.1M Jan 2024 financing.","Proceeds fund pivotal Phase III TIGeR-PaC trial through second interim readout (est. late 2024).","Financing also enables expansion of TAMP clinical pipeline into additional cancer indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244685,"accession_number":"0001493152-24-009978","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"RenovoRx promotes Leesa Gentry to CCO; salary $325k, option for 190k shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leesa Gentry promoted from SVP of Clinical Operations to Chief Clinical Officer, effective March 1, 2024.","Annual base salary of $325,000, with potential increase to $396,000 if CEO salary restored after 2024 reduction.","Eligible for annual discretionary bonus up to 35% of base salary; for 2024 bonus not pro-rated.","Received option to purchase 190,000 shares at $1.69 per share, vesting over 4 years in monthly installments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244684,"accession_number":"0001493152-24-007693","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2024-02-23T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"RenovoRx receives Nasdaq delisting notice for equity deficiency; COO resigns, new Chief Clinical Officer appointed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified RenovoRx on Feb 21, 2024 that it failed minimum stockholders' equity of $2.5M; delisting proceedings to begin unless hearing requested.","Company plans to request hearing, which will stay delisting pending panel decision; previously raised ~$6.1M in private placement to bolster equity.","Chief Operating Officer Angela Gill Nelms resigned effective March 1, 2024 for personal reasons, no disagreement with company.","Board appointed Leesa Gentry, current SVP Clinical Operations, as Chief Clinical Officer effective March 1, 2024, assuming clinical/regulatory duties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244683,"accession_number":"0001493152-24-005711","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2024-02-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"RenovoRx CFO James Ahlers resigns; VP Kocak named Principal Accounting Officer with $235K salary","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Ahlers resigned as CFO effective Feb 5, 2024, for personal reasons; no disagreement with the company.","Ronald B. Kocak, previously VP and Controller, appointed VP, Controller and Principal Accounting Officer effective Feb 9, 2024.","Kocak receives $235,000 base salary, up to 35% bonus, and option for 15,000 shares at $1.56, vesting over 4 years with double trigger.","Kocak will serve as principal financial and accounting officer; CFO position remains unfilled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244682,"accession_number":"0001493152-24-004083","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2024-01-29T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"RenovoRx closes $6.1M private placement; insider participation; exec salary cuts 25%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised gross proceeds of $6,111,695 via private placement of 6,133,414 shares + warrants at $0.99/share (non-insiders) and $1.22 (insiders).","Insiders including management and board purchased shares at $1.22, showing confidence.","25% reduction in base salaries for CEO Shaun Bagai, Ramtin Agah, Angela Gill Nelms until board decides otherwise.","2023 bonuses paid in 10-year options at $1.08 exercise price instead of cash.","Second interim analysis of TIGeR-PaC Phase III trial expected at 52nd event (death) in late 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244681,"accession_number":"0001493152-24-000024","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"RenovoRx announces death of board member David Diamond, Audit Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Diamond passed away on December 26, 2023; served on board since May 2021.","He was Chair of Audit Committee, member of Compensation Committee, and Lead Independent Director.","Company will seek a replacement for Diamond in due course."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262114,"accession_number":"0001493152-23-045272","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"RenovoRx shareholders approve equity issuance proposal allowing >20% share dilution at up to 10% discount","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Dec 15, 2023, shareholders approved Equity Issuance Proposal with 4,747,833 for, 336,779 against, 3,200 abstain.","Proposal allows issuance of shares or convertible securities exceeding 20% of outstanding common stock.","Issuance at a discount up to 10% below market price, in non-public offerings.","Quorum of 47.58% (5,087,812 shares) present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262113,"accession_number":"0001493152-23-040786","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RenovoRx Q3 net loss narrows to $1.4M on warrant gain; TIGeR-PaC trial advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.4M vs $2.1M YoY; includes $1.5M gain on fair value of common warrants.","Cash and equivalents $3.2M as of Sept 30, 2023; shares outstanding 10.7M.","R&D expense $1.6M, up 100% YoY, driven by Phase III TIGeR-PaC trial costs.","Phase III TIGeR-PaC trial for pancreatic cancer continues after interim analysis recommended continuation.","Collaboration with Imugene to expand TAMP platform into immunotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262112,"accession_number":"0001493152-23-039525","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"RenovoRx gets Nasdaq extension to Feb 19, 2024 for $2.5M equity compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted extension to February 19, 2024 to meet $2.5M stockholders' equity requirement (Rule 5550(b)(2)).","Company must evidence full compliance by deadline; failure triggers delist determination.","Delist determination can be stayed by request for hearing before Nasdaq Hearings Panel.","No assurance of compliance; risk of delisting if not met."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279330,"accession_number":"0001493152-23-032160","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"RenovoRx amends bylaws for universal proxy rules; appoints Dr. Spiegel to Compensation Committee","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board reduced stockholder meeting quorum from majority to one-third of voting power.","Enhanced disclosure requirements for stockholder nominations and proposals, aligning with Rule 14a-19.","Modified adjournment procedures and list of stockholders per DGCL amendments.","Dr. Robert Spiegel appointed to Compensation Committee; full committee rosters disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279329,"accession_number":"0001493152-23-030228","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2023-08-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"RenovoRx receives Nasdaq delisting notice for equity below $2.5M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of $1,188,000 as of June 30, 2023, below Nasdaq's $2.5M minimum requirement.","Company also fails alternative standards of $35M market value or $500K net income from continuing operations.","Has 45 days (by Oct 5, 2023) to submit plan to regain compliance; Nasdaq may grant up to 180-day extension.","Management intends to submit compliance plan but cannot assure acceptance or ability to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279328,"accession_number":"0001493152-23-029240","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2023-08-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RenovoRx Q2 net loss $2.3M; positive Phase III data shows 8-month progression delay","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.3M vs $2.6M year ago; cash $6.0M; R&D $1.9M, G&A $1.4M.","Phase III TIGeR-PaC: 8-month progression delay, 6-month OS benefit, 65% fewer adverse events.","Collaboration with Imugene to deliver oncolytic immunotherapy via TAMP platform for metastatic disease.","Appointed Robert Spiegel to Board, Margaret Tempero to SAB, Leesa Gentry as SVP Clinical Ops.","Closed $5M registered direct offering and concurrent private placement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297698,"accession_number":"0001493152-23-022862","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2023-06-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"RenovoRx announces positive interim Phase III data: RenovoGem delays progression by 8 months in pancreatic cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Interim Phase III data show RenovoGem delays cancer progression by 8 months in locally advanced pancreatic cancer.","RenovoRx issued press release on June 29, 2023 detailing positive interim results from ongoing trial.","RenovoGem is delivered via RenovoRx's proprietary targeted therapy platform for difficult-to-treat cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297697,"accession_number":"0001493152-23-020719","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"RenovoRx shareholders elect all 7 director nominees and ratify auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Each of the 7 director nominees received over 5 million votes for, with Ramtin Agah, M.D. and Shaun R. Bagai each getting 5,094,179 for.","Ratification of Baker Tilly US, LLP as independent auditor for FY2023 passed with 7,463,474 votes for, 22,982 against.","Broker non-votes totaled 2,374,191 on director elections; no broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297696,"accession_number":"0001493152-23-016947","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RenovoRx Q1 2023 net loss $3.3M; Phase III data shows 60% survival benefit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents were $3.7M at March 31, 2023; net loss $3.3M vs $3.0M in Q1 2022.","Phase III TIGeR-PaC interim analysis: 60% survival benefit, >65% reduction in side effects vs systemic chemo.","Closed $5M registered direct offering subsequent to quarter end.","Appointed Robert J. Spiegel (former CMO of Schering-Plough) to Board; Leesa Gentry as SVP Clinical Operations.","Issued 8th U.S. patent extending RenovoTAMP therapy platform IP coverage."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297695,"accession_number":"0001493152-23-013781","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"RenovoRx appoints former Schering-Plough CMO Robert Spiegel to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Spiegel appointed as independent director effective April 25, 2023; board size increased from 6 to 7.","He brings 40+ years biopharma experience, involved in over 30 FDA NDA approvals and multiple blockbuster drugs.","Received initial option award for 43,026 shares valued at $120,000, vesting monthly over 36 months.","Company plans to advance FDA discussions on RenovoGem Phase III interim data and new indications.","Dr. Spiegel also serves on boards of Geron, Cyclacel, Ayala, Athenex, and SPARC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297694,"accession_number":"0001493152-23-010652","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"RenovoRx raises $5M in registered direct offering and private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$5M from sale of 1,557,632 shares (or pre-funded warrants) at $3.21 per share.","Concurrent private placement of warrants to purchase 1,947,040 shares at $3.21, exercisable for 5.5 years.","Offering priced at-the-market under Nasdaq rules; closing on April 3, 2023.","Roth Capital Partners acted as exclusive placement agent; net proceeds for working capital and general corporate purposes.","Pre-funded warrants priced at $3.2099 each to avoid investor exceeding 4.99% beneficial ownership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317968,"accession_number":"0001493152-23-006504","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"RenovoRx reports FY2022 net loss $9.9M; Phase III pancreatic cancer trial interim analysis triggered","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $9.9M for FY2022 vs $6.3M in 2021; diluted EPS ($1.09) vs ($1.21).","Cash $6.4M as of Dec 31, 2022; expects to fund operations into Q3 2023.","Phase III TIGeR-PaC trial: first interim analysis triggered after 26 events (30% of 86); DMC review underway; results expected within a week.","47 of 114 target patients randomized; second interim analysis expected in 2024.","Operating expenses $10.0M, up from $5.7M; R&D $4.3M, G&A $5.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317967,"accession_number":"0001493152-23-001787","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2023-01-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"RenovoRx PK substudy shows >50% reduction in systemic drug exposure with RenovoTAMP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In 13 LAPC patients, intra-arterial gemcitabine via RenovoTAMP reduced systemic drug exposure by >50% vs IV.","Data presented at ASCO GI Symposium January 19-21, 2023, along with three additional abstracts.","TIGeR-PaC trial: 47 of 114 target patients randomized; 25 deaths reported to date.","Additional abstracts cover mesenteric venous thrombosis prevalence and SBRT vs IMRT tolerability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336233,"accession_number":"0001493152-22-031670","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RenovoRx reports Q3 net loss of $2.1M; cash at $8.1M; Phase III interim analysis expected Q4 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.1 million for Q3 2022, up from $1.5 million in Q3 2021.","Cash and short-term marketable securities of $8.1 million as of Sep 30, 2022; 9.07M shares outstanding.","G&A expenses rose to $1.3M from $0.6M, driven by post-IPO support and D&O insurance premiums.","Expects first prospective interim analysis of Phase III TIGeR-PaC trial in pancreatic cancer in Q4 2022.","Plans to launch Phase II/III trial in extrahepatic cholangiocarcinoma in Q4 2022/Q1 2023; appointed Angela Gill Nelms as COO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353647,"accession_number":"0001493152-22-026179","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2022-09-19T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"RenovoRx appoints Angela Gill Nelms as COO; $400K salary, stock option grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Angela Gill Nelms appointed COO effective Sept 19, 2022; previously COO at Florence Healthcare.","Annual base salary $400,000, discretionary bonus target 35%, option to purchase 274,230 shares.","Severance: 50% salary outside change-in-control, 100% plus full equity vesting during change-in-control period.","Company expects Phase 3 TIGeR-PaC interim analysis in Q4 2022; Nelms to oversee operations.","Also reimbursed up to $20,000 moving expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353646,"accession_number":"0001493152-22-022608","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RenovoRx reports Q2 2022 net loss of $2.6M; cash $10.8M; Phase 3 interim analysis expected Q4 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.6M for Q2 2022 vs $1.3M in Q2 2021; R&D expense $1.4M vs $0.5M.","Cash and equivalents and short-term marketable securities of $10.8M as of June 30, 2022.","Phase 3 TIGeR-PaC first prospective interim analysis expected in Q4 2022.","Protocol for Phase 2/3 trial in extrahepatic cholangiocarcinoma submitted to FDA; first patient enrollment planned Q4 2022.","Appointed James Ahlers as CFO and Ron Kocak as VP & Controller in July 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353645,"accession_number":"0001493152-22-019760","cik":1574094,"company_name":"RenovoRx, Inc.","ticker":"RNXT","form_type":"8-K","filed_at":"2022-07-19T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"RenovoRx names James Ahlers CFO, Chris Lehman resigns; Ronald Kocak added as VP/Controller","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Christopher Lehman resigned effective July 15, 2022 to pursue a new opportunity.","James Ahlers appointed CFO, Secretary and Treasurer effective July 15, 2022; will serve as principal financial and accounting officer.","Ahlers is a consultant from Danforth Advisors; RenovoRx pays Danforth $450/hour for his services.","Ronald B. Kocak, CPA, appointed VP and Controller; previously served as interim controller since October 2021.","Ahlers has over 25 years life science finance experience, including CFO of Intarcia Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":42633376.604531296,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-07-19T23:59:59+00:00|353645"}